Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$624.28M, compared with -$541.28M a year earlier.

Context

  • Retained earnings amounted to 462.2% of total assets at the end of Q1 FY2026, up 86.2 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -15.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$624.28M-3.2% QoQ
Last fiscal yearDec 2025
-$605.01M-17.6% YoY
Year agoMar 2025
-$541.28M-15.3% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.3%——
1 year-17.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(605.01M) USD
Year-over-year change
-17.6%

Retained Earnings vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's Mar 2026 retained earnings of -$624.28M is the 6th highest of the 11 companies compared; the peer median is -$636.97M.
  • Its year-over-year change of -15.3% is the 5th highest of 11, against a peer median of -18.3%.
  • Retained earnings amounts to 462.2% of total assets for TNYA, versus a peer median of 338.0%.
TNYA Competitors Peer median
Retained Earnings for TNYA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NAUTNautilus Biotechnology, Inc.Mar 2026-$346.72M -19.7%—195.0%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026-$429.96M -16.8%—136.6%
PYXSPyxis Oncology, Inc.Mar 2026-$466.45M -21.2%—725.4%
VYGRVoyager Therapeutics, Inc.Mar 2026-$473.84M -32.7%—216.0%
CRBUCaribou Biosciences, Inc.Mar 2026-$621.6M -27.3%—417.2%
TNYATenaya Therapeutics, Inc.Mar 2026-$624.28M -15.3%—462.2%
FHTXFoghorn Therapeutics Inc.Mar 2026-$652.34M -13.1%—293.6%
PRLDPrelude Therapeutics IncorporatedMar 2026-$693.45M -12.6%—579.6%
HUMAHumacyte, Inc.Mar 2026-$744.47M -15.1%—673.4%
ABEOAbeona Therapeutics Inc.Mar 2026-$759.15M +8.0%—382.5%
IMRXImmuneering CorporationMar 2026-$293.78B -122645.6%—136.8%
Peer median (excluding TNYA) -$636.97M-18.3%—338.0%

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents38.13M95.27M45.68M4.32M100.55M
Short-term Investments213.17M91.26M58.96M57.12M0
Net Receivables02.25M000
Inventory00000
Other Current Assets4.06M938K1.16M842K1.03M
Total Current Assets255.36M193.75M111.58M67.38M105.59M
Property, Plant & Equipment (Net)54.71M62.7M53.26M47.75M37.09M
Goodwill00000
Intangible Assets00000
Long-term Investments547K17.7M00419K
Tax Assets2.46M0000
Other Non-current Assets3.58M4.79M5.68M4.82M3.83M
Total Non-current Assets61.29M85.19M58.93M52.57M41.34M
Total Assets316.65M278.95M170.52M119.94M146.92M
Account Payables10.72M9.58M5.63M5.16M3.58M
Short-term Debt1.99M002.78M0
Tax Payables000348K0
Deferred Revenue00000
Other Current Liabilities5.39M6.97M9.27M5.81M6.19M
Total Current Liabilities21.77M24.25M22.73M15.98M15.44M
Long-term Debt00007.81M
Deferred Tax Liabilities2.46M0000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities182K228K253K281K410K
Total Non-current Liabilities16.35M11.32M8.36M11.11M8.22M
Total Liabilities38.12M35.57M31.09M27.09M23.66M
Common Stock4K7K7K8K21K
Retained Earnings(155.53M)(279.2M)(403.28M)(514.41M)(605.01M)
Accumulated OCI(141K)(378K)(106K)28K0
Other Stockholders Equity00000
Minority Interest00000
Total Equity278.53M243.38M139.42M92.85M123.27M
Total Debt15.7M15.1M12.42M13.61M10.83M
Net Debt(22.43M)(80.17M)(33.26M)9.29M(89.72M)

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.